查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1954269

动物用抗生素和抗菌药物市场分析及预测（至2035年）：类型、产品类型、应用、剂型、最终用户、技术、功能、阶段

Animal Antibiotics and Antimicrobials Market Analysis and Forecast to 2035: Type, Product, Application, Form, End User, Technology, Functionality, Stage
出版日期: | 出版商: Global Insight Services | 英文 303 Pages | 商品交期: 3-5个工作天内

价格
简介目录

兽用抗生素和抗菌药物市场预计将从2024年的7.214亿美元成长到2034年的9.8亿美元，复合年增长率约为3.4%。兽用抗生素和抗菌药物市场涵盖用于预防、控制和治疗牲畜和伴侣动物感染疾病的药物。市场的成长动力源自于保障动物健康和优化农业生产力的需求。法规结构和日益增长的抗菌素抗药性问题正在影响市场动态，促使人们开发替代疗法并制定合理的用药指南。

受对高效兽医保健解决方案日益增长的需求推动，兽用抗生素和抗菌药物市场正经历强劲增长。饲料添加剂领域已成为成长最快的细分市场，这主要得益于提高牲畜生产力和健康状况的需求。在该领域，四环霉素和青霉素类药物因其频谱抗菌活性和成本效益而特别突出。治疗领域紧随其后，口服和注射剂型因其能够精准治疗特定感染疾病而备受青睐。离子载体和大环内酯类药物也因其在预防疾病传播和促进动物生长方面的作用而得到更广泛的应用。随着水产品消费量的增长，对疾病控制的需求也日益增加，水产养殖业预计将显着扩张。此外，向永续和负责任的抗生素使用方式的转变，也为益生菌和益生元等替代解决方案的创新创造了机会。这些趋势凸显了市场的动态特性，并显示新兴技术和产品开发领域存在潜在的策略投资机会。

市场区隔
种类 四环霉素、青霉素类、大环内酯类、Aminoglycosides、磺胺类药物、Fluoroquinolones、林可酰胺类、头孢菌素类
产品 饲料添加剂、注射、口服粉末、口服液、乳房内製剂、预混合料
目的 家禽、猪、牛、水产养殖、伴侣动物
形式 液体、粉末、颗粒
最终用户 兽医诊所、畜牧场、研究机构
科技 离子载体，β-内酰胺类
功能 抗发炎、抗寄生虫
步 生长促进剂和治疗剂

兽用抗生素和抗菌药物市场呈现出动态的市场格局，主要参与者占了相当大的市场。定价策略竞争激烈，反映出市场对高效能兽药解决方案的持续需求。新产品频繁上市，其驱动力在于创新需求和应对不断出现的动物健康问题。市场正朝着更永续、更环保的抗菌药物方向发展，这与全球负责任的畜牧业趋势相符。竞争基准研究表明，老字型大小企业透过策略联盟和收购来保持其优势，占据着强大的市场地位。监管影响显着，严格的指导方针规范产品开发和市场准入。欧洲和北美高度监管的市场正在影响市场成长轨迹。在亚太和拉丁美洲等新兴市场，不断增长的牲畜数量和日益增强的动物健康意识创造了盈利的机会。技术进步和监管合规正在推动创新和扩张，使市场前景充满希望。

主要趋势和驱动因素：

由于人们对动物健康的日益关注以及全球肉类消费量的增长，兽用抗生素和抗菌药物市场正经历显着增长。市场趋势表明，畜牧业正朝着预防性医疗保健的方向发展，凸显了抗生素和抗菌药物在保障动物福利和生产力方面的重要性。对高品质肉类和乳製品的需求推动了对有效疾病控制解决方案的需求。兽医领域的科技创新正在促进新型抗生素和抗菌药物的研发，从而提高疗效和安全性。法规结构也在不断发展，更加重视产品的永续和负责任使用，这刺激了创新。此外，精准畜牧养殖技术的应用正在改善动物健康的监测和管理，进一步推动市场成长。新兴市场存在着许多机会，畜牧业的扩张正是为了因应不断变化的饮食习惯。能够提供经济高效解决方案的公司有望占据可观的市场份额。此外，製药公司与研究机构之间的合作正在加速发现新的化合物，以应对日益严重的抗菌素抗药性问题。随着相关人员将动物健康和食品安全放在首位，预计该市场将持续成长。

目录

第一章执行摘要

第二章 市集亮点

第三章 市场动态

  • 宏观经济分析
  • 市场趋势
  • 市场驱动因素
  • 市场机会
  • 市场限制
  • 复合年均成长率：成长分析
  • 影响分析
  • 新兴市场
  • 技术蓝图
  • 战略框架

第四章 细分市场分析

  • 市场规模及预测：依类型
    • 四环霉素
    • 青霉素
    • 大环内酯类
    • Aminoglycosides
    • 磺胺类药物
    • Fluoroquinolones
    • 林可酰胺类
    • 头孢菌素
  • 市场规模及预测：依产品划分
    • 饲料添加剂
    • 注射
    • 口服粉剂
    • 口服液
    • 乳房内製剂
    • 预混合料
  • 市场规模及预测：依应用领域划分
    • 家禽
    • 猪
    • 牛
    • 水产养殖
    • 伴侣动物
  • 市场规模及预测：依类型
    • 液体
    • 粉末
    • 颗粒
  • 市场规模及预测：依最终用户划分
    • 兽医诊所
    • 畜牧场
    • 研究所
  • 市场规模及预测：依技术划分
    • 离子载体
    • β-内酰胺类
  • 市场规模及预测：依功能划分
    • 抗发炎药
    • 抗寄生虫药物
  • 市场规模及预测：依发展阶段划分
    • 生长促进剂
    • 治疗药物

第五章 区域分析

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地区
  • 亚太地区
    • 中国
    • 印度
    • 韩国
    • 日本
    • 澳洲
    • 台湾
    • 亚太其他地区
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 西班牙
    • 义大利
    • 其他欧洲地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非
    • 撒哈拉以南非洲
    • 其他中东和非洲地区

第六章 市场策略

  • 需求与供给差距分析
  • 贸易和物流限制
  • 价格、成本和利润率趋势
  • 市场渗透率
  • 消费者分析
  • 法规概述

第七章 竞争讯息

  • 市场定位
  • 市场占有率
  • 竞争基准
  • 主要企业的策略

第八章 公司简介

  • Phibro Animal Health
  • Eco Animal Health
  • Huvepharma
  • Norbrook Laboratories
  • HIPRA
  • Vetoquinol
  • Ceva Animal Health
  • Kyoritsu Seiyaku
  • Dechra Pharmaceuticals
  • Zagro
  • Virbac
  • Biogenesis Bago
  • Lohmann Animal Health
  • Neogen Corporation
  • Biovet
  • Elanco Animal Health
  • Boehringer Ingelheim Vetmedica
  • Vetanco
  • Merial
  • Bimeda

第九章：关于我们

简介目录
Product Code: GIS20983

Animal Antibiotics and Antimicrobials Market is anticipated to expand from $721.4 million in 2024 to $980.0 million by 2034, growing at a CAGR of approximately 3.4%. The Animal Antibiotics and Antimicrobials Market encompasses pharmaceutical products designed to prevent, control, and treat infections in livestock and companion animals. This market is driven by the need to ensure animal health and optimize agricultural productivity. Regulatory frameworks and rising concerns over antimicrobial resistance are shaping market dynamics, prompting innovations in alternative therapies and prudent usage guidelines.

The Animal Antibiotics and Antimicrobials Market is experiencing robust growth, propelled by the escalating demand for effective veterinary healthcare solutions. The feed additives segment emerges as the top-performing sub-segment, driven by the need to enhance livestock productivity and health. Within this segment, tetracyclines and penicillins are particularly prominent, owing to their broad-spectrum efficacy and cost-effectiveness. The therapeutic segment trails closely, with oral and injectable formulations gaining traction for their precision in treating specific infections. Ionophores and macrolides are also witnessing increased adoption, reflecting their role in preventing disease spread and promoting growth in animals. The aquaculture sector is poised for significant expansion, as rising seafood consumption necessitates enhanced disease management. Furthermore, the shift towards sustainable and responsible antibiotic use presents opportunities for innovation in alternative solutions, such as probiotics and prebiotics. These trends underscore the market's dynamic nature, highlighting the potential for strategic investments in emerging technologies and product development.

Market Segmentation
TypeTetracyclines, Penicillins, Macrolides, Aminoglycosides, Sulfonamides, Fluoroquinolones, Lincosamides, Cephalosporins
ProductFeed Additives, Injectable, Oral Powders, Oral Solutions, Intramammary Preparations, Premixes
ApplicationPoultry, Swine, Cattle, Aquaculture, Companion Animals
FormLiquid, Powder, Granules
End UserVeterinary Clinics, Animal Farms, Research Institutes
TechnologyIonophore, Beta-lactam
FunctionalityAnti-inflammatory, Antiparasitic
StageGrowth Promoters, Therapeutics

The Animal Antibiotics and Antimicrobials Market demonstrates a dynamic landscape characterized by significant market share distribution among key players. Pricing strategies are competitive, reflecting the ongoing demand for effective veterinary solutions. New product launches are frequent, driven by innovation and the necessity to address emerging animal health concerns. The market is witnessing a shift towards more sustainable and eco-friendly antimicrobials, aligning with global trends in responsible animal husbandry. Competition benchmarking reveals a robust presence of established companies striving to maintain their dominance through strategic partnerships and acquisitions. Regulatory influences are substantial, with stringent guidelines shaping product development and market entry. The European and North American markets are heavily regulated, impacting growth trajectories. Emerging markets in Asia-Pacific and Latin America present lucrative opportunities due to increasing livestock populations and rising awareness of animal health. The market's future is promising, with technological advancements and regulatory compliance driving innovation and expansion.

Geographical Overview:

The animal antibiotics and antimicrobials market is witnessing notable growth across various regions, each exhibiting unique dynamics. North America holds a prominent position, driven by the extensive use of antibiotics in livestock and stringent regulatory frameworks. The region's focus on food safety and animal health further propels market expansion. Europe follows closely, with a strong emphasis on reducing antibiotic use in agriculture, fostering the development of alternative solutions. Asia Pacific is experiencing rapid growth due to increasing livestock production and rising awareness of animal health. Countries like China and India are emerging as significant contributors to market dynamics, with substantial investments in veterinary healthcare. In Latin America, the market is expanding as countries like Brazil and Argentina focus on enhancing livestock productivity. Meanwhile, the Middle East & Africa present untapped potential, with growing recognition of the importance of antibiotics and antimicrobials in improving animal health and productivity.

Global tariffs on animal antibiotics and antimicrobials are prompting strategic pivots in Japan, South Korea, China, and Taiwan. Japan and South Korea are enhancing domestic production capabilities to mitigate reliance on imports, while China accelerates its self-sufficiency drive amidst geopolitical tensions. Taiwan, with its robust pharmaceutical sector, remains pivotal but vulnerable to regional conflicts. The parent market is experiencing steady growth globally, driven by rising livestock production and heightened awareness of antimicrobial resistance. By 2035, the market is expected to evolve towards sustainable practices, with a focus on alternative solutions. Middle East conflicts contribute to volatility in energy prices, indirectly affecting supply chain costs and operational efficiencies, necessitating strategic adaptations to ensure resilience in this critical sector.

Key Trends and Drivers:

The Animal Antibiotics and Antimicrobials Market is experiencing notable growth due to rising awareness of animal health and increasing global meat consumption. Market trends reveal a shift towards preventive healthcare for livestock, emphasizing the importance of antibiotics and antimicrobials to ensure animal welfare and productivity. The demand for high-quality meat and dairy products is driving the need for effective disease management solutions. Technological advancements in veterinary medicine are fostering the development of novel antibiotics and antimicrobials, enhancing treatment efficacy and safety. Regulatory frameworks are evolving, focusing on sustainable and responsible use of these products, which is stimulating innovation. Moreover, the integration of precision livestock farming techniques is enabling better monitoring and management of animal health, further propelling market growth. Opportunities abound in emerging markets where livestock production is expanding to meet dietary shifts. Companies that can offer cost-effective and efficient solutions are poised to capture significant market share. Additionally, collaborations between pharmaceutical firms and research institutions are accelerating the discovery of new compounds, addressing the growing concern of antimicrobial resistance. This market is set for sustained expansion as stakeholders prioritize animal health and food security.

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Application
  • 2.4 Key Market Highlights by Form
  • 2.5 Key Market Highlights by End User
  • 2.6 Key Market Highlights by Technology
  • 2.7 Key Market Highlights by Functionality
  • 2.8 Key Market Highlights by Stage

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Tetracyclines
    • 4.1.2 Penicillins
    • 4.1.3 Macrolides
    • 4.1.4 Aminoglycosides
    • 4.1.5 Sulfonamides
    • 4.1.6 Fluoroquinolones
    • 4.1.7 Lincosamides
    • 4.1.8 Cephalosporins
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Feed Additives
    • 4.2.2 Injectable
    • 4.2.3 Oral Powders
    • 4.2.4 Oral Solutions
    • 4.2.5 Intramammary Preparations
    • 4.2.6 Premixes
  • 4.3 Market Size & Forecast by Application (2020-2035)
    • 4.3.1 Poultry
    • 4.3.2 Swine
    • 4.3.3 Cattle
    • 4.3.4 Aquaculture
    • 4.3.5 Companion Animals
  • 4.4 Market Size & Forecast by Form (2020-2035)
    • 4.4.1 Liquid
    • 4.4.2 Powder
    • 4.4.3 Granules
  • 4.5 Market Size & Forecast by End User (2020-2035)
    • 4.5.1 Veterinary Clinics
    • 4.5.2 Animal Farms
    • 4.5.3 Research Institutes
  • 4.6 Market Size & Forecast by Technology (2020-2035)
    • 4.6.1 Ionophore
    • 4.6.2 Beta-lactam
  • 4.7 Market Size & Forecast by Functionality (2020-2035)
    • 4.7.1 Anti-inflammatory
    • 4.7.2 Antiparasitic
  • 4.8 Market Size & Forecast by Stage (2020-2035)
    • 4.8.1 Growth Promoters
    • 4.8.2 Therapeutics

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Application
      • 5.2.1.4 Form
      • 5.2.1.5 End User
      • 5.2.1.6 Technology
      • 5.2.1.7 Functionality
      • 5.2.1.8 Stage
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Application
      • 5.2.2.4 Form
      • 5.2.2.5 End User
      • 5.2.2.6 Technology
      • 5.2.2.7 Functionality
      • 5.2.2.8 Stage
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Application
      • 5.2.3.4 Form
      • 5.2.3.5 End User
      • 5.2.3.6 Technology
      • 5.2.3.7 Functionality
      • 5.2.3.8 Stage
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Application
      • 5.3.1.4 Form
      • 5.3.1.5 End User
      • 5.3.1.6 Technology
      • 5.3.1.7 Functionality
      • 5.3.1.8 Stage
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Application
      • 5.3.2.4 Form
      • 5.3.2.5 End User
      • 5.3.2.6 Technology
      • 5.3.2.7 Functionality
      • 5.3.2.8 Stage
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Application
      • 5.3.3.4 Form
      • 5.3.3.5 End User
      • 5.3.3.6 Technology
      • 5.3.3.7 Functionality
      • 5.3.3.8 Stage
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Application
      • 5.4.1.4 Form
      • 5.4.1.5 End User
      • 5.4.1.6 Technology
      • 5.4.1.7 Functionality
      • 5.4.1.8 Stage
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Application
      • 5.4.2.4 Form
      • 5.4.2.5 End User
      • 5.4.2.6 Technology
      • 5.4.2.7 Functionality
      • 5.4.2.8 Stage
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Application
      • 5.4.3.4 Form
      • 5.4.3.5 End User
      • 5.4.3.6 Technology
      • 5.4.3.7 Functionality
      • 5.4.3.8 Stage
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Application
      • 5.4.4.4 Form
      • 5.4.4.5 End User
      • 5.4.4.6 Technology
      • 5.4.4.7 Functionality
      • 5.4.4.8 Stage
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Application
      • 5.4.5.4 Form
      • 5.4.5.5 End User
      • 5.4.5.6 Technology
      • 5.4.5.7 Functionality
      • 5.4.5.8 Stage
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Application
      • 5.4.6.4 Form
      • 5.4.6.5 End User
      • 5.4.6.6 Technology
      • 5.4.6.7 Functionality
      • 5.4.6.8 Stage
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Application
      • 5.4.7.4 Form
      • 5.4.7.5 End User
      • 5.4.7.6 Technology
      • 5.4.7.7 Functionality
      • 5.4.7.8 Stage
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Application
      • 5.5.1.4 Form
      • 5.5.1.5 End User
      • 5.5.1.6 Technology
      • 5.5.1.7 Functionality
      • 5.5.1.8 Stage
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Application
      • 5.5.2.4 Form
      • 5.5.2.5 End User
      • 5.5.2.6 Technology
      • 5.5.2.7 Functionality
      • 5.5.2.8 Stage
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Application
      • 5.5.3.4 Form
      • 5.5.3.5 End User
      • 5.5.3.6 Technology
      • 5.5.3.7 Functionality
      • 5.5.3.8 Stage
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Application
      • 5.5.4.4 Form
      • 5.5.4.5 End User
      • 5.5.4.6 Technology
      • 5.5.4.7 Functionality
      • 5.5.4.8 Stage
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Application
      • 5.5.5.4 Form
      • 5.5.5.5 End User
      • 5.5.5.6 Technology
      • 5.5.5.7 Functionality
      • 5.5.5.8 Stage
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Application
      • 5.5.6.4 Form
      • 5.5.6.5 End User
      • 5.5.6.6 Technology
      • 5.5.6.7 Functionality
      • 5.5.6.8 Stage
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Application
      • 5.6.1.4 Form
      • 5.6.1.5 End User
      • 5.6.1.6 Technology
      • 5.6.1.7 Functionality
      • 5.6.1.8 Stage
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Application
      • 5.6.2.4 Form
      • 5.6.2.5 End User
      • 5.6.2.6 Technology
      • 5.6.2.7 Functionality
      • 5.6.2.8 Stage
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Application
      • 5.6.3.4 Form
      • 5.6.3.5 End User
      • 5.6.3.6 Technology
      • 5.6.3.7 Functionality
      • 5.6.3.8 Stage
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Application
      • 5.6.4.4 Form
      • 5.6.4.5 End User
      • 5.6.4.6 Technology
      • 5.6.4.7 Functionality
      • 5.6.4.8 Stage
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Application
      • 5.6.5.4 Form
      • 5.6.5.5 End User
      • 5.6.5.6 Technology
      • 5.6.5.7 Functionality
      • 5.6.5.8 Stage

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Phibro Animal Health
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Eco Animal Health
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Huvepharma
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Norbrook Laboratories
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 HIPRA
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Vetoquinol
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Ceva Animal Health
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Kyoritsu Seiyaku
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Dechra Pharmaceuticals
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Zagro
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Virbac
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Biogenesis Bago
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Lohmann Animal Health
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Neogen Corporation
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Biovet
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Elanco Animal Health
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Boehringer Ingelheim Vetmedica
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Vetanco
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Merial
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Bimeda
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us